Bank Julius Baer & Co. Ltd Zurich Has $220,000 Stake in Danaher Corporation $DHR

Bank Julius Baer & Co. Ltd Zurich cut its stake in Danaher Corporation (NYSE:DHR) by 6.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,114,584 shares of the conglomerate’s stock after selling 79,139 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.16% of Danaher worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in DHR. Boyd Watterson Asset Management LLC OH raised its position in Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after buying an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its stake in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after acquiring an additional 53 shares in the last quarter. 1834 Investment Advisors Co. raised its holdings in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 54 shares during the last quarter. Bruce G. Allen Investments LLC lifted its position in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares in the last quarter. Finally, Texas Bank & Trust Co boosted its holdings in Danaher by 1.6% during the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. TD Cowen lifted their price target on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Evercore ISI raised their price objective on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

DHR opened at $227.34 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The business has a 50 day moving average of $208.58 and a 200-day moving average of $202.11. The stock has a market cap of $160.58 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the business earned $1.71 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.